ArticleJournal of medicinal chemistry2026
Discovery of Highly Selective Noncovalent Macrocyclic Peptide Inhibitors Suppressing Both TMPRSS2 Protease Activity and Viral Receptor Function.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The type II transmembrane serine protease TMPRSS2 plays a critical role in respiratory virus entry, including SARS-CoV-2. Using an mRNA display platform with genetic code reprogramming, we identified macrocyclic peptide (MCP) inhibitors of TMPRSS2 that bound to the TMPRSS2 active site. The most potent MCPs displayed picomolar binding affinities and excellent selectivity across a panel of 22 trypsin-fold serine proteases. Although the lead MCP showed strong in vitro potency, proteolytic instability reduced its cellular activity. Rational optimization yielded a stability-enhanced variant, T2-MCP-19, which bound TMPRSS2 with high affinity (KD = 80 pM) and inhibited the uptake of virus-like particles pseudotyped with SARS-CoV-2 spike protein in lung epithelial Calu-3 cells with nanomolar potency. Notably, several MCPs exhibited dual functionality by inhibiting both the enzymatic and receptor functions of TMPRSS2, as demonstrated by their blockade of the HKU1 coronavirus spike protein binding. These results highlight MCPs as promising, highly selective TMPRSS2-directed antiviral lead compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.